What's New

Modules 1, 2 & 3 - Reader Training

Module Three Reader Training
Stefano Fanti, MD
Full Professor, Diagnostic Imaging at University of Bologna
Director, Nuclear Medicine Division and PET Center,
The Policlinico S. Orsola Director, Oncology Department,
IRCCS AOU Policlinico S. Orsola, Bologna, Italy
Andrea Farolfi, MD
Division of Nuclear Medicine, S. Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria, Bologna, Italy
PSMA Reader Training Module 3 | Part One, Part Two & Part Three is designed to assist the reader in reading PSMA PET/CT with confidence by navigating challenging cases, addressing pitfalls, providing clear direction for patient management in the PSMA PET/CT report, and developing skills to become a consultant to the referring physician(s).
Module Two Reader Training
Jaideep S. Sohi, MD
President and Founder
American Molecular Imaging
PSMA Reader Training Module 2 is designed to improve PSMA PET/CT reader skills and increase the reader’s confidence by reviewing; the PSMA expression scoring, providing an understanding of how 68GA PSMA-11 varies from other PET Tracers (FDG, Choline, Fluciclovine), determining normal vs abnormal findings, explaining tips to navigate challenging 68GA PSMA-11 PET/CT cases, and developing the consultative role of the interpreting physician.
Module One Reader Training
Nat Lenzo, MD
Clinical Director of Theranostics and Molecular Imaging
Genesis Care
PSMA Reader Training Module 1 | Part One & Part Two provides a basic understanding of the clinical applications of 68Ga PSMA-11 PET/CT scans, develops skills to effectively read 68Ga PSMA-11 PET/CT, reviews the process for reading scans, supports implementation of scanning protocols for 68Ga PSMA-11 PET/CT, specifies when to order 68Ga PSMA-11 and improves reader confidence through workstation display of comprehensive case study reviews.
Featured Program

Clinical Utility of PSMA PET/CT in Prostate Imaging

Insights into the Urology/Oncology Perspective

Presented by: Sanoj Punnen, MD, MAS  |  Preston C. Sprenkle, MD
Scott T. Tagawa, MD, MS, FACP  |  Clint D. Bahler, MD, MS
Prostate Cancer Training

This program is designed to enlighten the Prostate cancer care team about the importance of PSMA Imaging and its impact on patient management and care. This multidisciplinary panel discussion provides clinical perspectives on the utility and the implications of using PSMA PET/CT as a theranostic approach and identifies best practices through the shared clinical experiences of Urologists and Medical Oncologists.

Featured Case Study
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
R. Jeffrey Karnes, MD, FACS   |  Mohamed E Ahmed, MBBCh
 Combination Therapy Improves Efficacy in Widespread Prostate Metastatic Disease

A 69-year-old man presented with a persistent rising prostate specific antigen (PSA) of 15.8 ng/mL in September 2019. The patient’s previous PSA readings were 11.4 ng/mL in November 2018 and 12.9 ng/mL in May 2019.

The patient had a known history of prostate cancer and was treated initially with Radical Retropubic Prostatectomy (RRP) for Gleason 3 + 4 = 7. The patient subsequently experienced biochemical recurrences and was treated with salvage external beam radiation therapy, intermittent hormone therapy with leuprolide, and 3 cycles of Provenge.